Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Director/PDMR dealing

22 Dec 2014 07:00

RNS Number : 4158A
Plethora Solutions Holdings PLC
22 December 2014
 



 

 

22 December 2014

 

Plethora Solutions Holdings PLC

 

("Plethora" or the "Company")Director/PDMR dealing

 

Plethora Solutions Holdings PLC (AIM: PLE) announces that it has approved amendments to the Company' Long Term Incentive Scheme (LTIP) to ensure key managers are appropriately remunerated and incentivised to enable the Company to achieve its strategic objectives. These arrangements will replace any previous entitlements in place in relation to the LTIP Scheme as they applied to these individuals.

 

All awards under the LTIP are subject to the Company securing certain specified achievement milestones. Under the criteria set, shares will only actually vest with the individuals upon a change of control event or if the individual ceases to be employed or engaged with the Company or Group under "good leaver" or acceptable circumstances.

 

Individual

Ordinary shares awarded under LTIP

Total shareholding following award under LTIP

Percentage holding on a fully diluted basis

Jamie Gibson, CEO

35,000,000

35,000,000

3.6%

Jim Mellon,* Chairman

1,000,000

146,812,298

15.2%

Mike Collis,** CFO

1,000,000

24,654,806

2.6%

Dr Greg Bailey, Non Executive Director

1,000,000

1,555,600

0.16%

Romero Tayong, Company Secretary

200,000

200,000

-

 

Notes

 

* the holdings of Jim Mellon include those directly beneficially owned by him together with those held by investment funds in which he has an indirect beneficial interest;

** the LTIP award has been granted to Mike Collis in his personal capacity as a director of the Company. Mike Collis is also engaged as a consultant by Maven Capital partners (UK) LLP which in turn is the appointed manager of Capital for Enterprise Fund A LLP, an investment fund which holds 23,654,806 Ordinary Shares in the Company.

 

As a result of these awards, the fully diluted share capital of the Company will increase to 971,090,768 Ordinary Shares.

 

 

 

 

Plethora Solutions

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

 

Tel : +44(0) 20 3077 5400

finnCap (Nomad & Broker)

Geoff Nash/James Thompson

Stephen Norcross

Tel : +44(0) 20 7220 0500

(Corporate Finance)

(Corporate Broking)

Citigate Dewe Rogerson

David Dible

Malcolm Robertson

 

Tel: +44(0) 20 7282 2949

Tel: +44(0) 20 7282 2867

 

 

About Plethora

 

Plethora is focused on commercialising FORTACIN™ for the treatment of premature ejaculation with strategic marketing partners and obtaining NDA approval for FORTACIN™ with the FDA.

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE LN). Further information is available at www.plethorasolutions.co.uk 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAKAAAAPLFEF
Date   Source Headline
18th Sep 201410:37 amRNSResult of General Meeting
17th Sep 201410:39 amRNSGeneral Meeting Update
16th Sep 20149:38 amRNSHolding(s) in Company
16th Sep 20148:00 amRNSLicensing Agreement signed with Recordati
8th Sep 20144:18 pmRNSIssue of Equity
2nd Sep 20147:00 amRNSFurther Regarding General Meeting
29th Aug 20144:21 pmRNSConditional Subscription to raise £2.3million
29th Aug 20142:37 pmRNSINTERIM RESULTS
29th Aug 20142:30 pmRNSFundraising and Notice of General Meeting
29th Aug 20142:30 pmRNSRestoration - Plethora Solutions Holdings plc
29th Aug 20148:00 amRNSSuspension - Plethora Solutions Holdings plc
10th Jun 201410:42 amRNSResult of AGM
19th May 20147:00 amRNSLoan repayment
7th May 201410:36 amRNSHolding(s) in Company
25th Apr 20145:00 pmRNSUpdated investor presentation
23rd Apr 20147:00 amRNSAnnual Financial Report and notice of AGM
22nd Apr 201410:49 amRNSPreliminary Results for the year ended 31 Dec 2013
26th Mar 20147:00 amRNSManufacturing Appointment
11th Mar 20148:12 amRNSCompany update
3rd Feb 20148:45 amRNSCompany update and Investor presentation
13th Jan 201410:57 amRNSHolding(s) in Company
20th Dec 20133:34 pmRNSCEO Appointment
18th Dec 201310:37 amRNSHolding(s) in Company
16th Dec 20134:52 pmRNSAward of LTIPs
29th Nov 20137:00 amRNSAward of LTIPs & Issue of Ordinary Shares
28th Nov 20137:01 amRNSConversion of Loan Notes
28th Nov 20137:00 amRNSResignation of CEO
22nd Nov 20137:00 amRNSCommercial Update
19th Nov 20137:00 amRNSEuropean Commission Approval
4th Nov 20139:40 amRNSHolding(s) in Company
4th Nov 20139:05 amRNSTotal Voting Rights
4th Nov 20137:00 amRNSHolding(s) in Company
31st Oct 201311:04 amRNSResult of GM
28th Oct 201311:10 amRNSHolding(s) in Company
16th Oct 201310:50 amRNSHolding(s) in Company
15th Oct 20133:16 pmRNSPlacing & Subscription to raise £4.4 million
15th Oct 20133:14 pmRNSExercise of warrant
30th Sep 20137:00 amRNSINTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2013
27th Sep 201312:11 pmRNSHolding(s) in Company
27th Sep 201312:06 pmRNSHolding(s) in Company
20th Sep 20131:13 pmRNSPositive CHMP Opinion
12th Sep 20137:00 amRNSBoard Changes
22nd Aug 20137:00 amRNSGlobal expansion of commercialisation of PSD502
1st Jul 201312:07 pmRNSAGM Statement & PSD502 Regulatory Update
18th Jun 20133:23 pmRNSNotice of Results and AGM
17th Jun 20131:21 pmRNSHolding(s) in Company
7th Jun 20137:00 amRNSPreliminary Results for the year ended 31 Dec 2012
12th Apr 201310:30 amRNSDirectorate Change
4th Apr 20132:17 pmRNSResult of GM
18th Mar 20131:09 pmRNSPlacing to raise £2.124m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.